top of page

Search

Day One Announces Updated FIREFLY-1 Data for Tovorafenib

Sep 11, 20231 min read

Today, Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling New Drug Application (NDA) submission to U.S. Food and Drug Administration (FDA) for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG). Read more HERE.

Recent Posts

AWS is providing $10 million to accelerate research for pediatric health care and to better understand rare diseases.

Day One Biopharmaceuticals Announces FDA approved of New Drug Application for relapsed or refractory pediatric low-grade glioma (pLGG)

Children’s National Hospital Receives $96 Million for Rare Brain Tumor Research & Care

Comments

bottom of page